CM
COGT icon

Castleark Management’s Cogent Biosciences COGT Stock Holding History

Castleark Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.86M Buy
99,870
+35,920
+56% +$1.26M 0.1% 179
2026
Q1 		$2.46M Buy
+63,950
New +$2.36M 0.08% 192

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Castleark Management's COGT Position: Q2 2026 in Review

Castleark Management increased its Cogent Biosciences (COGT) stake by 56% in Q2 2026, buying an estimated $1.26M and bringing the position to 99,870 shares worth $3.86M. The position accounts for 0.1% of the portfolio, ranked #179.

Castleark Management first reported a position in COGT in Q1 2026 and has held it in 2 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Castleark Management held 99,870 shares of Cogent Biosciences worth $3.86M as of Q2 2026.
  • Castleark Management bought 35,920 Cogent Biosciences shares in Q2 2026, an estimated $1.26M.
  • Cogent Biosciences made up 0.1% of Castleark Management's portfolio in Q2 2026, its #179 holding.
  • Castleark Management first reported a position in Cogent Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.